Efficacy and Safety of Dapagliflozin in Polycystic Ovary Syndrome: a Multicentre, Randomized, Placebo-controlled Trial
Latest Information Update: 30 Jun 2023
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms DEAP
Most Recent Events
- 11 Jan 2023 Status changed from active, no longer recruiting to completed.
- 21 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Apr 2022.
- 21 Feb 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Apr 2022.